Bradley J. Monk, MD
Professor
Creighton University School of Medicine, St. Joseph’s Hospital and Medical Center
Division of Gynecologic Oncology
500 W Thomas Rd Suite 680
Phoenix,,
AZ
USA
85013
Biographical Sketch: Dr. Monk is currently Professor and Director in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. Dr. Monk is also a Professor on the Clinical Scholar Track at the University of Arizona College of Medicine – Phoenix. Dr. Monk’s research interests include chemotherapy to treat ovarian and cervical carcinoma; the etiology, biomarkers in gynecologic cancers; and quality of life in women with advanced ovarian cancer. He is on the Board of Directors for the Gynecologic Oncology Group (GOG) and is the Group’s Cervical and Vulvar Committee Chair. Additionally, Dr. Monk is an investigator for the GOG and also a member of the Publications committee, Protocol Development committee and Immunotherapy subcommittee. Dr. Monk is a fellow of the American College of Surgeons, the American College of Obstetricians and Gynecologists and the American Society for Colposcopy and Cervical Pathology, as well as being an active member of the Society of Gynecologic Oncologists, the American Society of Clinical Oncology and the American Association for Cancer Research and other professional organizations. He is a current member of the editorial boards of several journals, including Gynecologic Oncology and Clinical Ovarian Cancer, and a reviewer for journals including Clinical Cancer Research, Obstetrics and Gynecology, Cancer and Journal of Clinical Oncology. Dr. Monk has authored more than 175 peer-reviewed articles along with 26 book chapters dealing predominantly with the prevention and chemotherapy of gynecologic malignancies and patient quality of life."
Papers:
1 - Seminal Abstracts
Seminal Abstract: Presentation of seminal clinical data from Gynecologic Oncology Group study 262 presented at the European Society of Gynecologic Oncology
4 - Seminal Abstract
A phase III, randomized, double-blind trialof weekly paclitaxel plus the angiopoientin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1
5 - Scientific Plenary
A cost-utility analysis of Gynecologic Oncology Group protocol 218: the importance of incorporating prospectively collected quality-of-life scores in health outcomes research
62 - Scientific Plenary
Ascites predicts degree of treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, Fallopian tube, and peritoneal cancers
89 - Featured Poster
Characteristics of high-volume gynecologic cancer centers – framework toward centers of excellence: a National Cancer Data Base (NCDB) study
99 - Featured Poster
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in subjects with advanced ovarian cancer: exploratory analysis of phase III OVA-301 study
101 -Featured Poster
Evaluation of CA-125 response in the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer
138 - Scientific Plenary
Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer
139 - Scientific Plenary
Health-related quality of life associated with every-3-week paclitaxel vs dose-dense weekly paclitaxel in combination with carboplatin with or without bevacizumab for primary ovarian cancer: Gynecologic Oncology Group study 262
143 - Scientific Plenary
Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study
144 - Scientific Plenary
High-risk patients with recurrent/advanced cervical cancer may derive the most benefit from antiangiogenesis therapy: a Gynecologic Oncology Group (GOG) study
379 - Poster Session B
The use of a geographic information system to identify advanced cervical cancer patients in California
Questions & Panel Discussion
Debate: Costs and Quality of Life: Anti Angiogenesis Agents Should be Used Earlier in Treatment